Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Trading 01-20 13:47:42 EST

35.52

-2.16

-5.73%

High36.77	Low35.03	Vol377.97K
Open36.10	D1 Closing37.68	Amplitude4.62%
Mkt Cap722.53M	Tradable Cap624.95M	Total Shares20.34M
T/O13.52M	T/O Rate2.15%	Tradable Shares17.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":35.52,"timestamp":1768934859706,"preClose":37.68,"halted":0,"volume":377969,"delay":0,"changeRate":-0.05732484076433112,"floatShares":17594200,"shares":20341589,"eps":-7.899717,"marketStatus":"Trading","change":-2.16,"latestTime":"01-20 13:47:42 EST","open":36.1,"high":36.765,"low":35.025,"amount":13524619.803088002,"amplitude":0.046178,"askPrice":35.58,"askSize":100,"bidPrice":35.53,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-7.899717,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768942800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":37.68,"preHourTrading":{"tag":"盘前","latestPrice":36.09,"preClose":37.68,"latestTime":"09:28 EST","volume":2395,"amount":87049.60405,"timestamp":1768919281156,"change":-1.59,"changeRate":-0.042197,"amplitude":0.044055},"postHourTrading":{"tag":"盘后","latestPrice":37.87,"preClose":37.68,"latestTime":"19:55 EST","volume":21477,"amount":809278.17,"timestamp":1768611318815,"change":0.19,"changeRate":0.005042,"amplitude":0},"volumeRatio":0.666272,"impliedVol":0.9685,"impliedVolPercentile":0.42},"requestUrl":"/m/hq/s/NKTR/tweets","defaultTab":"tweets","newsList":[{"id":"2602318239","title":"Septerna appoints Mark Wilson as chief legal officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318239","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318239?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:16","pubTimestamp":1767906989,"startTime":"0","endTime":"0","summary":"Septerna (SEPN) announced the appointment of Mark Wilson as chief legal officer. Wilson joins Septerna from Nektar Therapeutics (NKTR), where he mo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/septerna-appoints-mark-wilson-as-chief-legal-officer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/septerna-appoints-mark-wilson-as-chief-legal-officer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","SEPN","BK4007"],"gpt_icon":0},{"id":"2593337453","title":"Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2593337453","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593337453?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:19","pubTimestamp":1766438340,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what investors need to know.What To Know: While the study for severe alopecia areata demonstrated a proof-of-concept, it narrowly missed its primary endpoint for the full patient cohort.The investigational biologic failed to achieve statistical significance in the intent-to-treat analysis, showing a mean SALT score reduction of 28.2% and 30.3% in the treatment arms versus 11.2% for placebo .However, Nektar reported that when excluding four patients with major eligibility violations, both dosage arms achieved statistical significance . The company highlighted that rezpegaldesleukin more than doubled the treatment effect of placebo and plans to advance the drug into Phase 3 development in 2026.Despite the sell-off, Wall Street analysts responded with bullish revisions following the data release. BTIG maintaine","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/22/Nov-2--2019-San-Francisco-----Ca-----Usa.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/22/Nov-2--2019-San-Francisco-----Ca-----Usa.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49549831/nektar-therapeutics-nktr-stock-slides-despite-analyst-optimism-on-alopecia-data","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49549831/nektar-therapeutics-nktr-stock-slides-despite-analyst-optimism-on-alopecia-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2592995830","title":"Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995830","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592995830?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:06","pubTimestamp":1765922771,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. has appointed Minnie Kuo as Chief Operating Officer, effective immediately. Kuo joined the company in September 2023 as Chief Development Officer and has over 20 years of experience in biotechnology and pharmaceuticals, with prior leadership roles at Vir Biotechnology, Nektar Therapeutics, and Gilead Sciences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL3FFM7N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4566","SG9999015986.USD","BK4550","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","NKTR","BK4007","LU0058720904.USD","LU0320765992.SGD","LU1674673428.USD","IE0002270589.USD","IE00B19Z3581.USD","LU1066051498.USD","LU2089984988.USD","PLRX","LU0823416689.USD","BK4535","SG9999015952.SGD","BK4588","BK4568","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU1585245621.USD","LU0889565916.HKD","BK4139","LU1066053197.SGD","LU1571399168.USD","SG9999015945.SGD","BK4532","GILD","IE00BKVL7J92.USD","LU0114720955.EUR","LU1778281490.HKD","BK4585","LU2324357040.USD","LU2087621335.USD","LU2468319806.SGD","LU1839511570.USD","BK4578","SG9999015978.USD","BK4583","LU0234570918.USD","LU1674673691.USD","IE00BSNM7G36.USD","LU0289739699.SGD","IE00B3T34201.USD","VIR","LU0109394709.USD"],"gpt_icon":0},{"id":"2592953795","title":"Why Nektar Therapeutics (NKTR) Is Down 9.3% After Phase 2b REZOLVE-AA Data Readout And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2592953795","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592953795?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:23","pubTimestamp":1765920239,"startTime":"0","endTime":"0","summary":"On 15 December 2025, Nektar Therapeutics held an investor call to review topline 36-week induction data from its ongoing Phase 2b REZOLVE-AA trial of rezpegaldesleukin, an investigational Treg-proliferating therapy for severe-to-very-severe alopecia areata.\nThis readout is important because it offers an early test of whether Nektar’s lead immune-modulating asset can show meaningful benefit in a high-need dermatology indication.\nWe’ll now examine how this Phase 2b rezpegaldesleukin readout in...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/why-nektar-therapeutics-nktr-is-down-93-after-phase-2b-rezol","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/why-nektar-therapeutics-nktr-is-down-93-after-phase-2b-rezol","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4153","AA","BK4585","BK4588","NKTR","BK4007"],"gpt_icon":0},{"id":"2592931680","title":"HC Wainwright Adjusts Nektar Therapeutics Price Target to $135 From $120, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2592931680","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592931680?lang=en_us&edition=fundamental","pubTime":"2025-12-17 02:04","pubTimestamp":1765908278,"startTime":"0","endTime":"0","summary":"Price: 50.50, Change: -2.80, Percent Change: -5.25","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"gpt_icon":0},{"id":"2592931577","title":"Nektar Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2592931577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592931577?lang=en_us&edition=fundamental","pubTime":"2025-12-17 02:02","pubTimestamp":1765908120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 13:02 ET (18:02 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0},{"id":"2592399309","title":"Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2592399309","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592399309?lang=en_us&edition=fundamental","pubTime":"2025-12-17 00:30","pubTimestamp":1765902600,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before eligibility adjustments.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/16/Nov-2--2019-San-Francisco-----Ca-----Usa.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/16/Nov-2--2019-San-Francisco-----Ca-----Usa.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/25/12/49426419/nektar-alopecia-trial-misses-endpoint-hits-significance-after-patient-exclusion","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/25/12/49426419/nektar-alopecia-trial-misses-endpoint-hits-significance-after-patient-exclusion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["EASI","BSA","BK4007","NKTR"],"gpt_icon":0},{"id":"2591987219","title":"BUZZ-Nektar falls after autoimmune disorder drug misses main goal in mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2591987219","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591987219?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:59","pubTimestamp":1765893566,"startTime":"0","endTime":"0","summary":"BUZZ-Nektar falls after autoimmune disorder drug misses main goal in mid-stage study ** Shares of drug developer Nektar Therapeutics NKTR.O fall 6.8% to $50 premarket** Co says its experimental drug for alopecia areata, rezpegaldesleukin, narrowly missed the main goal of achieving statistically significant reduction in severity in a mid-stage study ** Says both treatment arms met statistical significance on the main goal when excluding four patients with major study eligibility violations** Alopecia areata is an autoimmune condition where the body's immune system attacks hair follicles, causing patchy hair loss on the scalp** Co plans to move into late-stage development for the drug in 2026** As of last close, stock has more than tripled YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nL4N3XM0UA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2591677987","title":"Nektar Therapeutics Shares Down 2.4% Premarket After Its Autoimmune Disorder Drug Misses Main Goal in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2591677987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591677987?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:43","pubTimestamp":1765892587,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM0A3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2591873309","title":"BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2591873309","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591873309?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:37","pubTimestamp":1765892250,"startTime":"0","endTime":"0","summary":"BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt DropDec 16 (Reuters) - Nektar Therapeutics NKTR.O:NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM09W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2591982841","title":"Nektar Therapeutics - Both Rezpegaldesleukin Treatment Arms Met Statistical Significance Excluding Violations","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591982841?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:06","pubTimestamp":1765890365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM09W:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2591828449","title":"Nektar Therapeutics - Rezolve-Aa Phase 2B Study Results Supports Advancement to Phase 3 Development in Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2591828449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591828449?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:06","pubTimestamp":1765890365,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM09W:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2591698284","title":"Nektar Therapeutics - Rezpegaldesleukin Well Tolerated With Consistent Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2591698284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591698284?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:06","pubTimestamp":1765890365,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM09W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2591598282","title":"Nektar Therapeutics - Rezolve-Aa Phase 2B Study Achieved Target Product Profile With 28.2% Salt Score Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2591598282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591598282?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:06","pubTimestamp":1765890365,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM09W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2591984560","title":"Nektar Study Establishes Proof-of-Concept in Patients with Severe Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2591984560","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591984560?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:44","pubTimestamp":1765889040,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition.Mean percent reduction in SALT scores, a measurement for scalp hair loss, at 36 weeks was 30% for both treatment arms versus 6% for placebo. The results achieved statistical significance when excluding four patients that didn't meet major study eligibility criteria.The safety profile showed the drug was well tolerated.The company plans to advance the drug into a phase three program for the treatment of alopecia areata in 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2591981248","title":"Nektar Therapeutics Reports Positive Phase 2b Results for Rezpegaldesleukin in Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981248","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981248?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:30","pubTimestamp":1765888254,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics announced topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial evaluating rezpegaldesleukin, an investigational IL-2 pathway agonist, in patients with severe-to-very-severe alopecia areata. The study randomized 92 patients to receive one of two doses of rezpegaldesleukin or placebo via subcutaneous injection twice monthly. The primary endpoint was the mean percentage reduction from baseline in the Severity of Alopecia Tool  score at Week 36. Rezpegaldesleukin demonstrated a favorable safety and tolerability profile, with nearly all treatment-emergent adverse events reported as mild-to-moderate and self-resolving. The discontinuation rate due to adverse events was 1.4% in the combined treatment arms, and no patients discontinued due to injection site reactions. Nektar plans to submit the REZOLVE-AA results for presentation at a medical conference in 2026. Data from an ongoing 16-week treatment extension are expected in early Q2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL5ysDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2591981182","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:25 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981182","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981182?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:25","pubTimestamp":1765887900,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:25 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nAQN2LDRL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2591098313","title":"Nektar Therapeutics Jumps Pre-Bell Ahead of Phase 2b Topline Results for Alopecia Areata Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2591098313","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591098313?lang=en_us&edition=fundamental","pubTime":"2025-12-16 18:26","pubTimestamp":1765880815,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Jumps Pre-Bell Ahead of Phase 2b Topline Results for Alopecia Areata Treatment","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2591020627","title":"Nektar to Hold Conference Call to Discuss Topline Results From the 36-Week Induction Treatment Period for Its Rezolve-Aa Phase 2B Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2591020627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591020627?lang=en_us&edition=fundamental","pubTime":"2025-12-16 07:00","pubTimestamp":1765839600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA50F2XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2589843528","title":"Nektar Therapeutics Grants Stock Options to New Employees Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2589843528","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589843528?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:00","pubTimestamp":1764975611,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics has granted non-qualified stock options to two newly hired employees under its 2025 Inducement Plan. One employee received options to purchase 7,260 shares at an exercise price of $60.35 per share, based on the closing price on November 25, 2025. The other employee received options for 11,050 shares at an exercise price of $57.69 per share, the closing price on December 4, 2025. The options have an eight-year term and will vest over four years, with a quarter of the shares vesting after one year and the remainder vesting monthly over the next three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDLbTw9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0511},{"period":"1month","weight":-0.1706},{"period":"3month","weight":-0.3478},{"period":"6month","weight":0.5108},{"period":"1year","weight":1.8171},{"period":"ytd","weight":-0.1088}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.038129},{"month":2,"riseRate":0.516129,"avgChangeRate":0.003089},{"month":3,"riseRate":0.387097,"avgChangeRate":-0.002052},{"month":4,"riseRate":0.451613,"avgChangeRate":0.01158},{"month":5,"riseRate":0.354839,"avgChangeRate":0.003107},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}